Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Depreciation and Depletion (2016 - 2022)

Lexaria Bioscience's Depreciation and Depletion history spans 8 years, with the latest figure at $23893.0 for Q2 2022.

  • For Q2 2022, Depreciation and Depletion fell 14.45% year-over-year to $23893.0; the TTM value through May 2022 reached $105916.0, down 5.99%, while the annual FY2021 figure was $111718.0, 0.92% down from the prior year.
  • Depreciation and Depletion for Q2 2022 was $23893.0 at Lexaria Bioscience, down from $26163.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $28875.0 in Q3 2020 and bottomed at $462.0 in Q1 2018.
  • The 5-year median for Depreciation and Depletion is $26853.5 (2019), against an average of $20274.2.
  • The largest annual shift saw Depreciation and Depletion soared 4200.95% in 2019 before it decreased 14.45% in 2022.
  • A 5-year view of Depreciation and Depletion shows it stood at $1603.0 in 2018, then surged by 1616.28% to $27512.0 in 2019, then increased by 1.52% to $27929.0 in 2020, then grew by 0.0% to $27930.0 in 2021, then fell by 14.45% to $23893.0 in 2022.
  • Per Business Quant, the three most recent readings for LEXX's Depreciation and Depletion are $23893.0 (Q2 2022), $26163.0 (Q1 2022), and $27930.0 (Q4 2021).